Cassava Begin Period Cash Flow vs Depreciation Analysis

SAVA Stock

USD 2.89 0.05 1.70%

Cassava Sciences financial indicator trend analysis is way more than just evaluating Cassava Sciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cassava Sciences is a good investment. Please check the relationship between Cassava Sciences Begin Period Cash Flow and its Depreciation accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Cassava Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Cassava Stock refer to our How to Trade Cassava Stock guide.

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cassava Sciences Begin Period Cash Flow account and Depreciation. At this time, the significance of the direction appears to have strong relationship.

The correlation between Cassava Sciences' Begin Period Cash Flow and Depreciation is 0.72. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Depreciation in the same time period over historical financial statements of Cassava Sciences, assuming nothing else is changed. The correlation between historical values of Cassava Sciences' Begin Period Cash Flow and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Cassava Sciences are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Begin Period Cash Flow i.e., Cassava Sciences' Begin Period Cash Flow and Depreciation go up and down completely randomly.

Correlation Coefficient

0.72

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Cassava Sciences value has been used up. For tax purposes Cassava Sciences can deduct the cost of the tangible assets it purchases as business expenses. However, Cassava Sciences must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Cassava Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cassava Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Cassava Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Cassava Stock refer to our How to Trade Cassava Stock guide.At present, Cassava Sciences' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 777.5 M, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.

	2021	2022	2023	2024 (projected)
Net Interest Income	49K	2.8M	7.8M	8.2M
Interest Income	49K	2.8M	7.8M	8.2M

Net Interest Income Interest Income

Cassava Sciences fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Other Current Liab	Non Currrent Assets Other	Current Deferred Revenue	Short Term Debt	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.71	0.98	0.84	-0.99	-0.6	0.65	0.99	0.86	1.0	0.29	0.39	0.82	-0.01	0.92	0.83	0.25	0.82	1.0	0.77	0.88	0.8	-0.02	-0.23	0.85	-0.72
Total Current Liabilities	0.71		0.57	0.62	-0.67	-0.55	0.64	0.66	0.63	0.71	0.33	0.48	0.55	0.52	0.6	0.61	0.75	0.62	0.71	0.23	0.76	0.85	0.15	-0.15	0.62	-0.41
Total Stockholder Equity	0.98	0.57		0.83	-0.97	-0.57	0.61	0.98	0.84	0.97	0.25	0.32	0.82	-0.21	0.92	0.81	0.03	0.8	0.97	0.83	0.82	0.69	-0.08	-0.23	0.83	-0.74
Property Plant And Equipment Net	0.84	0.62	0.83		-0.85	-0.84	0.91	0.78	1.0	0.81	0.27	0.27	0.93	-0.25	0.97	0.95	0.13	1.0	0.83	0.51	0.91	0.67	-0.02	-0.18	0.98	-0.8
Net Debt	-0.99	-0.67	-0.97	-0.85		0.61	-0.66	-0.99	-0.86	-0.99	-0.29	-0.39	-0.84	0.05	-0.93	-0.84	-0.22	-0.82	-1.0	-0.79	-0.89	-0.8	0.05	0.24	-0.86	0.74
Retained Earnings	-0.6	-0.55	-0.57	-0.84	0.61		-0.86	-0.53	-0.83	-0.57	-0.61	-0.31	-0.89	0.19	-0.75	-0.94	-0.17	-0.86	-0.59	-0.27	-0.72	-0.56	0.36	0.5	-0.82	0.76
Accounts Payable	0.65	0.64	0.61	0.91	-0.66	-0.86		0.56	0.9	0.61	0.31	0.31	0.86	-0.21	0.81	0.88	0.2	0.92	0.63	0.19	0.88	0.59	-0.05	-0.19	0.92	-0.67
Cash	0.99	0.66	0.98	0.78	-0.99	-0.53	0.56		0.79	0.99	0.27	0.38	0.77	-0.03	0.88	0.77	0.19	0.75	0.99	0.82	0.83	0.77	-0.05	-0.23	0.79	-0.69
Non Current Assets Total	0.86	0.63	0.84	1.0	-0.86	-0.83	0.9	0.79		0.82	0.26	0.27	0.93	-0.24	0.98	0.95	0.14	1.0	0.84	0.53	0.92	0.68	-0.02	-0.18	0.98	-0.81
Cash And Short Term Investments	1.0	0.71	0.97	0.81	-0.99	-0.57	0.61	0.99	0.82		0.29	0.41	0.8	0.03	0.9	0.8	0.28	0.78	1.0	0.78	0.86	0.81	-0.03	-0.23	0.82	-0.7
Net Receivables	0.29	0.33	0.25	0.27	-0.29	-0.61	0.31	0.27	0.26	0.29		0.53	0.39	0.08	0.25	0.5	0.2	0.27	0.29	0.11	0.32	0.2	-0.87	-0.97	0.24	-0.27
Common Stock Total Equity	0.39	0.48	0.32	0.27	-0.39	-0.31	0.31	0.38	0.27	0.41	0.53		0.25	0.28	0.27	0.34	0.39	0.27	0.4	0.06	0.37	0.34	-0.3	-0.45	0.3	0.08
Common Stock Shares Outstanding	0.82	0.55	0.82	0.93	-0.84	-0.89	0.86	0.77	0.93	0.8	0.39	0.25		-0.3	0.91	0.98	0.07	0.93	0.81	0.6	0.84	0.7	-0.2	-0.33	0.95	-0.89
Non Current Liabilities Total	-0.01	0.52	-0.21	-0.25	0.05	0.19	-0.21	-0.03	-0.24	0.03	0.08	0.28	-0.3		-0.24	-0.23	0.91	-0.24	0.01	-0.22	-0.04	0.4	0.29	0.06	-0.26	0.3
Other Current Assets	0.92	0.6	0.92	0.97	-0.93	-0.75	0.81	0.88	0.98	0.9	0.25	0.27	0.91	-0.24		0.92	0.1	0.96	0.91	0.67	0.91	0.69	-0.03	-0.19	0.95	-0.82
Other Stockholder Equity	0.83	0.61	0.81	0.95	-0.84	-0.94	0.88	0.77	0.95	0.8	0.5	0.34	0.98	-0.23	0.92		0.15	0.95	0.82	0.52	0.87	0.68	-0.26	-0.42	0.95	-0.84
Total Liab	0.25	0.75	0.03	0.13	-0.22	-0.17	0.2	0.19	0.14	0.28	0.2	0.39	0.07	0.91	0.1	0.15		0.14	0.27	-0.13	0.32	0.63	0.27	-0.02	0.13	0.01
Property Plant And Equipment Gross	0.82	0.62	0.8	1.0	-0.82	-0.86	0.92	0.75	1.0	0.78	0.27	0.27	0.93	-0.24	0.96	0.95	0.14		0.8	0.46	0.9	0.66	-0.02	-0.18	0.98	-0.79
Total Current Assets	1.0	0.71	0.97	0.83	-1.0	-0.59	0.63	0.99	0.84	1.0	0.29	0.4	0.81	0.01	0.91	0.82	0.27	0.8		0.78	0.87	0.81	-0.03	-0.23	0.84	-0.71
Common Stock	0.77	0.23	0.83	0.51	-0.79	-0.27	0.19	0.82	0.53	0.78	0.11	0.06	0.6	-0.22	0.67	0.52	-0.13	0.46	0.78		0.48	0.53	-0.1	-0.17	0.5	-0.68
Other Current Liab	0.88	0.76	0.82	0.91	-0.89	-0.72	0.88	0.83	0.92	0.86	0.32	0.37	0.84	-0.04	0.91	0.87	0.32	0.9	0.87	0.48		0.75	-0.02	-0.22	0.91	-0.71
Non Currrent Assets Other	0.8	0.85	0.69	0.67	-0.8	-0.56	0.59	0.77	0.68	0.81	0.2	0.34	0.7	0.4	0.69	0.68	0.63	0.66	0.81	0.53	0.75		0.21	-0.05	0.7	-0.62
Current Deferred Revenue	-0.02	0.15	-0.08	-0.02	0.05	0.36	-0.05	-0.05	-0.02	-0.03	-0.87	-0.3	-0.2	0.29	-0.03	-0.26	0.27	-0.02	-0.03	-0.1	-0.02	0.21		0.95	0.0	0.14
Short Term Debt	-0.23	-0.15	-0.23	-0.18	0.24	0.5	-0.19	-0.23	-0.18	-0.23	-0.97	-0.45	-0.33	0.06	-0.19	-0.42	-0.02	-0.18	-0.23	-0.17	-0.22	-0.05	0.95		-0.15	0.24
Net Tangible Assets	0.85	0.62	0.83	0.98	-0.86	-0.82	0.92	0.79	0.98	0.82	0.24	0.3	0.95	-0.26	0.95	0.95	0.13	0.98	0.84	0.5	0.91	0.7	0.0	-0.15		-0.78
Retained Earnings Total Equity	-0.72	-0.41	-0.74	-0.8	0.74	0.76	-0.67	-0.69	-0.81	-0.7	-0.27	0.08	-0.89	0.3	-0.82	-0.84	0.01	-0.79	-0.71	-0.68	-0.71	-0.62	0.14	0.24	-0.78

Click cells to compare fundamentals

Cassava Sciences Account Relationship Matchups

Cassava Sciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.5M	94.3M	266.8M	234.8M	151.7M	114.4M
Total Current Liabilities	1.4M	1.9M	12.5M	7.1M	14.2M	7.4M
Total Stockholder Equity	22.1M	92.2M	253.9M	227.5M	137.5M	80.1M
Property Plant And Equipment Net	137K	306K	20.8M	23.0M	21.9M	22.9M
Net Debt	(23.0M)	(93.2M)	(233.2M)	(200.9M)	(121.1M)	(115.1M)
Retained Earnings	(168.6M)	(174.9M)	(207.3M)	(283.6M)	(380.8M)	(361.7M)
Accounts Payable	453K	911K	7.1M	4.0M	10.6M	11.1M
Cash	23.1M	93.5M	233.4M	201.0M	121.1M	69.6M
Non Current Assets Total	137K	306K	22.3M	23.6M	22.0M	23.1M
Cash And Short Term Investments	23.1M	93.5M	233.4M	201.0M	121.1M	100.9M
Common Stock Total Equity	7K	17K	22K	35K	40K	39.3K
Common Stock Shares Outstanding	17.4M	26.1M	39.4M	40.2M	41.9M	44.0M
Liabilities And Stockholders Equity	23.5M	94.3M	266.8M	234.8M	151.7M	114.4M
Non Current Liabilities Total	294K	543K	235K	333K	232K	0.0
Other Current Assets	268K	945K	11.0M	11.1M	7.5M	7.9M
Other Stockholder Equity	191.6M	267.1M	461.2M	511.0M	518.2M	544.1M
Total Liab	1.4M	2.1M	12.9M	7.3M	14.2M	24.9M
Property Plant And Equipment Gross	137K	11K	20.8M	23.0M	24.1M	25.3M
Total Current Assets	23.3M	94.0M	244.5M	211.2M	129.6M	110.4M
Common Stock	190.7M	267.1M	461.2M	511.1M	42K	39.9K
Other Current Liab	9K	838K	5.2M	2.8M	3.6M	3.8M
Non Currrent Assets Other	(1K)	90K	295K	399K	359.1K	305.9K
Net Tangible Assets	22.1M	92.2M	252.8M	226.9M	261.0M	274.0M
Retained Earnings Total Equity	(164.0M)	(168.6M)	(174.9M)	(207.3M)	(186.6M)	(195.9M)
Capital Surpluse	183.6M	190.7M	267.1M	461.2M	530.4M	556.9M
Property Plant Equipment	47K	306K	20.8M	23.0M	26.4M	27.8M
Net Invested Capital	22.1M	92.2M	253.9M	227.5M	137.5M	119.8M
Net Working Capital	22.0M	92.1M	231.9M	204.2M	115.4M	109.2M
Capital Stock	22K	35K	40K	42K	48.3K	36.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Cassava Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cassava Sciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cassava Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cassava Sciences Stock:

How To Invest In Cassava

Details

Is Cassava Stock a good investment?

Details

What is Cassava Sciences' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Cassava Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For information on how to trade Cassava Stock refer to our How to Trade Cassava Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cassava Sciences. If investors know Cassava will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cassava Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.38)

Return On Assets

(0.46)

Return On Equity

(0.11)

The market value of Cassava Sciences is measured differently than its book value, which is the value of Cassava that is recorded on the company's balance sheet. Investors also form their own opinion of Cassava Sciences' value that differs from its market value or its book value, called intrinsic value, which is Cassava Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cassava Sciences' market value can be influenced by many factors that don't directly affect Cassava Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cassava Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cassava Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cassava Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cassava Begin Period Cash Flow vs Depreciation Analysis

Begin Period Cash Flow vs Depreciation

Begin Period Cash Flow vs Depreciation Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Depreciation

Cassava Sciences fundamental ratios Correlations

Cassava Sciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cassava Sciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Short Term Debt	- 0.97	Net Receivables
Net Debt	- 0.97	Total Stockholder Equity